Capricor Therapeutics (CAPR) Tops Q3 EPS by 5c

Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.25), $0.05 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $6.19 million versus the consensus estimate of $3.15 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline